BRAF and cancer: Recent studies have also found that presence of the BRAF mutation has direct implications for clinical management as along with TNM stage, BRAF mutational status was the only molecular variable that independently accounted for poor survival [13], and studies have found that BRAF mutant cancers are refractory to anti-EGRF therapy [14, 15].